Zhejiang Jianfeng Group Co., Ltd. Stock

Equities

600668

CNE000000B18

Construction Materials

End-of-day quote Shanghai S.E. 06:00:00 2024-05-16 pm EDT 5-day change 1st Jan Change
9.27 CNY +0.54% Intraday chart for Zhejiang Jianfeng Group Co., Ltd. +1.53% -16.11%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2022 3.56B 492M Sales 2023 2.89B 400M Capitalization 3.8B 526M
Net income 2022 288M 39.84M Net income 2023 93M 12.86M EV / Sales 2022 1.26 x
Net Debt 2022 109M 15.09M Net Debt 2023 341M 47.18M EV / Sales 2023 1.43 x
P/E ratio 2022
15.2 x
P/E ratio 2023
40.6 x
Employees 2,104
Yield 2022
1.18%
Yield 2023
-
Free-Float 76.01%
More Fundamentals * Assessed data
Dynamic Chart
Zhejiang Jianfeng's Pharmaceutical Unit Gets Nod to Market Anti-Tumor Drug MT
Jianfeng Group's Pharma Unit Gets Nod to Sell Glaucoma Eye Drops MT
Zhejiang Jianfeng Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Jianfeng Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zhejiang Jianfeng Unit's Gastroesophageal Reflux Drug Chosen for China's Centralized Procurement MT
Zhejiang Jianfeng Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jianfeng Group's Pharmaceutical Unit Gets US FDA's Nod to Trial Lung Cancer Drug MT
Zhejiang Jianfeng's Unit Gets Nod to Make Changes to Mycophenolate Mofetil Capsules MT
Zhejiang Jianfeng Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Jianfeng Registers Valsartan Amlodipine Tablet in China MT
Zhejiang Jianfeng Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Jianfeng Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Production Line of Zhejiang Jianfeng's Pharma Unit Passes Regulatory Inspection MT
Zhejiang Jianfeng Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Jianfeng Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
More news
1 day+0.54%
1 week+1.53%
Current month+5.34%
1 month+6.92%
3 months+1.76%
6 months-18.47%
Current year-16.11%
More quotes
1 week
9.05
Extreme 9.05
9.31
1 month
8.56
Extreme 8.56
9.31
Current year
7.94
Extreme 7.94
11.24
1 year
7.94
Extreme 7.94
12.35
3 years
7.94
Extreme 7.94
25.65
5 years
7.94
Extreme 7.94
25.65
10 years
7.94
Extreme 7.94
25.65
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 08-09-04
Director of Finance/CFO 51 14-11-11
Director/Board Member 59 08-09-04
Members of the board TitleAgeSince
Director/Board Member 69 17-05-18
Chairman 60 07-08-16
Director/Board Member 45 20-11-16
More insiders
Date Price Change Volume
24-05-17 9.27 +0.54% 3,004,601
24-05-16 9.22 +1.32% 3,558,559
24-05-15 9.1 -0.33% 1,653,988
24-05-14 9.13 +0.88% 2,101,380
24-05-13 9.05 -0.88% 2,242,388

End-of-day quote Shanghai S.E., May 16, 2024

More quotes
ZHE JIANG JIAN FENG GROUP CO., LTD is a China-based company, principally engaged in the manufacture and distribution of cement and pharmaceuticals. The Company mainly conducts its cement business in Hubei Province, Yunnan Province, Zhejiang Province and Guangxi Province. The Company provides pharmaceuticals, including anti-infective drugs, antipyretic and analgesic drugs, drugs for cardiovascular system diseases, drugs for diabetes mellitus, bulk drugs, intermediates and over the counter (OTC) products. The Company is also engaged in the provision of health products, and the manufacture and distribution of cables. The Company conducts its business in domestic markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 600668 Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW